Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ARMEN JIRAIR MOUGHAMIAN

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1932527306
CMS profile
2043875
Location
SAN FRANCISCO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$209,598.83

159 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Lilly USA, LLC $102,460.91 72
Eisai Inc. $60,430.12 68
Eisai Co., Ltd. $29,760.00 4
Eli Lilly and Company $10,012.79 12
Life Molecular Imaging Ltd $5,222.51 2
Biogen, Inc. $1,712.50 1

Page 2 of 4; records 51–100 of 159 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ARMEN JIRAIR MOUGHAMIAN

NPI 1932527306 · CMS profile ID 2043875

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

SAN FRANCISCO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 159 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1932527306?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ARMEN JIRAIR MOUGHAMIAN, NPI 1932527306, CMS profile ID 2043875. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 159 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1932527306?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). ARMEN JIRAIR MOUGHAMIAN, NPI 1932527306, CMS profile ID 2043875. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 159 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1932527306?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
ARMEN JIRAIR MOUGHAMIAN, NPI 1932527306, CMS profile ID 2043875, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 159 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1932527306?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

159 matching records · $209,598.83 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 159 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 159.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Eisai Inc. $32.7308/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244462957 CMS
Eisai Inc. $84.0407/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244462961 CMS
Eisai Inc. $14.5307/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244462965 CMS
Lilly USA, LLC $121.5907/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186517305 CMS
Life Molecular Imaging Ltd $90.2407/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1254410718 CMS
Lilly USA, LLC $937.5006/27/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1186520835 CMS
Eisai Inc. $106.5706/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244462904 CMS
Eisai Inc. $31.3506/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244462933 CMS
Eisai Co., Ltd. $6,400.0006/25/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1244462912 CMS
Lilly USA, LLC $9.7006/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186485237 CMS
Lilly USA, LLC $950.0006/16/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186485235 CMS
Lilly USA, LLC $5,937.5006/16/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186517303 CMS
Lilly USA, LLC $950.0006/13/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186476487 CMS
Lilly USA, LLC $2,500.0006/13/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186524625 CMS
Lilly USA, LLC $605.7006/10/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186518595 CMS
Lilly USA, LLC $47.1706/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186518609 CMS
Eisai Inc. $173.5006/06/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1244462989 CMS
Eisai Inc. $205.0006/06/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1244463016 CMS
Lilly USA, LLC $2,500.0006/06/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186521383 CMS
Lilly USA, LLC $1,575.0006/06/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186521385 CMS
Eisai Inc. $91.1806/05/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1244463117 CMS
Eisai Inc. $1,462.5006/05/2025 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: NEW
06/30/2026 1244463125 CMS
Eisai Inc. $30.2006/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244463142 CMS
Eisai Inc. $104.2606/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244463153 CMS
Eisai Inc. $3,510.0006/05/2025 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: NEW
06/30/2026 1244463157 CMS
Lilly USA, LLC $674.5506/04/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186518593 CMS
Lilly USA, LLC $1,575.0006/03/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186522163 CMS
Lilly USA, LLC $2,500.0006/03/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186524623 CMS
Lilly USA, LLC $25.1205/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186476489 CMS
Lilly USA, LLC $958.9505/29/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186476481 CMS
Lilly USA, LLC $113.5305/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186524629 CMS
Eisai Inc. $5,850.0005/28/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1244462942 CMS
Eisai Inc. $4,680.0005/28/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1244462946 CMS
Eisai Inc. $592.9505/28/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1244462949 CMS
Eisai Inc. $73.3205/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244462953 CMS
Lilly USA, LLC $2,500.0005/19/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186518605 CMS
Lilly USA, LLC $1,575.0005/19/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186518607 CMS
Lilly USA, LLC $114.7605/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186476485 CMS
Lilly USA, LLC $801.4305/14/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186524619 CMS
Eisai Inc. $108.4805/12/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1244463000 CMS
Eisai Inc. $216.7805/12/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1244463008 CMS
Lilly USA, LLC $2,500.0005/12/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186517299 CMS
Lilly USA, LLC $950.0005/12/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186517301 CMS
Eisai Inc. $292.5005/09/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1244462936 CMS
Lilly USA, LLC $686.9405/07/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186520217 CMS
Lilly USA, LLC $1,250.0005/05/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186522161 CMS
Eisai Inc. $1,187.5005/04/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1244462969 CMS
Eisai Inc. $17.4205/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244462929 CMS
Eisai Inc. $1,462.5005/01/2025 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: NEW
06/30/2026 1244463121 CMS
Eisai Inc. $1,462.5005/01/2025 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: NEW
06/30/2026 1244463129 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2020 $2,304.00 1
PY2021 $19,433.62 20
PY2022 $75,193.71 87
PY2023 $39,620.65 36
PY2024 $207,991.41 178
PY2025 $209,598.83 159

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $3.55 1
PY2025 Principal investigator $416,462.19 92
PY2024 Principal investigator $90,538.03 7
PY2023 Recipient $290.70 1
PY2023 Principal investigator $199,016.95 3
PY2022 Recipient $1,722.00 1
PY2022 Principal investigator $6.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

93 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48.00 12/31/2025 Covered Recipient Teaching Hospital
Sutter Amador Hospital
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215523011
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48.00 12/31/2025 Covered Recipient Teaching Hospital
Sutter Amador Hospital
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215523013
Principal investigator 1 Alnylam Pharmaceuticals Inc. $103.00 12/08/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521716
Principal investigator 1 Alnylam Pharmaceuticals Inc. $436.00 12/03/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521712
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,733.00 12/03/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521714
Principal investigator 1 Alnylam Pharmaceuticals Inc. $436.00 12/03/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521718
Principal investigator 1 Alnylam Pharmaceuticals Inc. $436.00 12/03/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521720
Principal investigator 1 Alnylam Pharmaceuticals Inc. $436.00 12/03/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521722
Principal investigator 1 Alnylam Pharmaceuticals Inc. $436.00 12/03/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521724
Principal investigator 1 Alnylam Pharmaceuticals Inc. $436.00 12/03/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521726
Principal investigator 1 Alnylam Pharmaceuticals Inc. $436.00 11/19/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521702
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,733.00 11/19/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521704
Principal investigator 1 Alnylam Pharmaceuticals Inc. $16,072.00 11/19/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521706
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,869.00 11/19/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521708
Principal investigator 1 Alnylam Pharmaceuticals Inc. $12,249.00 11/19/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521710
Principal investigator 1 Alnylam Pharmaceuticals Inc. $436.00 11/19/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521728
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48.00 10/31/2025 Covered Recipient Teaching Hospital
Sutter Amador Hospital
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215523007
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48.00 10/31/2025 Covered Recipient Teaching Hospital
Sutter Amador Hospital
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215523017
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48.00 10/28/2025 Covered Recipient Teaching Hospital
Sutter Amador Hospital
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215523009
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48.00 10/28/2025 Covered Recipient Teaching Hospital
Sutter Amador Hospital
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215523015
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,770.00 10/16/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521686
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15,271.00 10/16/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521688
Principal investigator 1 Alnylam Pharmaceuticals Inc. $726.00 10/16/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521690
Principal investigator 1 Alnylam Pharmaceuticals Inc. $13,638.00 10/16/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521692
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,869.00 10/16/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521694
Principal investigator 1 Alnylam Pharmaceuticals Inc. $436.00 10/16/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521696
Principal investigator 1 Alnylam Pharmaceuticals Inc. $12,249.00 10/16/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521698
Principal investigator 1 Alnylam Pharmaceuticals Inc. $16,072.00 10/16/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521700
Principal investigator 1 Alnylam Pharmaceuticals Inc. $436.00 10/16/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521730
Principal investigator 1 Alnylam Pharmaceuticals Inc. $436.00 10/16/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521732
Principal investigator 1 Alnylam Pharmaceuticals Inc. $12,249.00 10/16/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521734
Principal investigator 1 Alnylam Pharmaceuticals Inc. $436.00 10/16/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521736
Principal investigator 1 Alnylam Pharmaceuticals Inc. $436.00 10/16/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521738
Principal investigator 1 Alnylam Pharmaceuticals Inc. $13,638.00 10/16/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521740
Principal investigator 1 Alnylam Pharmaceuticals Inc. $13,638.00 10/16/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521742
Principal investigator 1 Alnylam Pharmaceuticals Inc. $436.00 10/16/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521744
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,869.00 10/16/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521746
Principal investigator 1 Alnylam Pharmaceuticals Inc. $726.00 10/16/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521748
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15,271.00 10/16/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521750
Principal investigator 1 Alnylam Pharmaceuticals Inc. $726.00 10/16/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521752
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15,271.00 10/16/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521754
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48.00 09/30/2025 Covered Recipient Teaching Hospital
Sutter Amador Hospital
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215523137
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48.00 09/30/2025 Covered Recipient Teaching Hospital
Sutter Amador Hospital
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215523139
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.84 09/17/2025 Covered Recipient Teaching Hospital
Sutter Medical Center - Sacramento
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215507262
Principal investigator 1 Alnylam Pharmaceuticals Inc. $18.77 09/17/2025 Covered Recipient Teaching Hospital
Sutter Amador Hospital
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215523145
Principal investigator 1 Alnylam Pharmaceuticals Inc. $10,000.00 09/03/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521674
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,540.00 09/03/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521676
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48.00 08/29/2025 Covered Recipient Teaching Hospital
Sutter Amador Hospital
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215523135
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48.00 08/29/2025 Covered Recipient Teaching Hospital
Sutter Amador Hospital
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215523141
Principal investigator 1 Alnylam Pharmaceuticals Inc. $206.00 08/15/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521650
Principal investigator 1 Alnylam Pharmaceuticals Inc. $103.00 08/15/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521654
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,500.00 08/13/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521664
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,538.00 08/13/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521666
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,800.00 08/13/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521668
Principal investigator 1 Alnylam Pharmaceuticals Inc. $4,579.00 08/01/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521656
Principal investigator 1 Alnylam Pharmaceuticals Inc. $206.00 08/01/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521658
Principal investigator 1 Alnylam Pharmaceuticals Inc. $236.00 08/01/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521660
Principal investigator 1 Alnylam Pharmaceuticals Inc. $93.00 08/01/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521662
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48.00 07/31/2025 Covered Recipient Teaching Hospital
Sutter Amador Hospital
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215523133
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48.00 07/31/2025 Covered Recipient Teaching Hospital
Sutter Amador Hospital
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215523143
Principal investigator 1 Alnylam Pharmaceuticals Inc. $13,638.00 07/23/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521652
Principal investigator 1 Alnylam Pharmaceuticals Inc. $75.00 07/20/2025 Covered Recipient Teaching Hospital
Sutter Medical Center - Sacramento
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215507249
Principal investigator 1 Alnylam Pharmaceuticals Inc. $12,249.00 07/02/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521670
Principal investigator 1 Alnylam Pharmaceuticals Inc. $436.00 07/02/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521672
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48.00 06/30/2025 Covered Recipient Teaching Hospital
Sutter Amador Hospital
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215523085
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48.00 06/30/2025 Covered Recipient Teaching Hospital
Sutter Amador Hospital
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215523099
Principal investigator 1 Alnylam Pharmaceuticals Inc. $436.00 06/23/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521642
Principal investigator 1 Alnylam Pharmaceuticals Inc. $726.00 06/23/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521644
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,869.00 06/23/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521646
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48.00 05/30/2025 Covered Recipient Teaching Hospital
Sutter Amador Hospital
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215523083
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48.00 05/30/2025 Covered Recipient Teaching Hospital
Sutter Amador Hospital
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215523097
Principal investigator 1 Alnylam Pharmaceuticals Inc. $13,638.00 05/02/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521634
Principal investigator 1 Alnylam Pharmaceuticals Inc. $726.00 05/02/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521636
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,869.00 05/02/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521638
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15,271.00 05/02/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521640
Principal investigator 1 Alnylam Pharmaceuticals Inc. $13,638.00 05/02/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521648
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48.00 04/30/2025 Covered Recipient Teaching Hospital
Sutter Amador Hospital
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215523081
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48.00 04/30/2025 Covered Recipient Teaching Hospital
Sutter Amador Hospital
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215523095
Recipient Eli Lilly and Company $3.55 04/29/2025 Covered Recipient Physician A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187871643
Principal investigator 1 Eli Lilly and Company $4,812.00 04/08/2025 Covered Recipient Teaching Hospital
CPMC-R.K. DAVIES MEDICAL CENTER
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187871265
Principal investigator 1 Alnylam Pharmaceuticals Inc. $13,638.00 04/02/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521630
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,113.60 04/02/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215521632
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48.00 03/31/2025 Covered Recipient Teaching Hospital
Sutter Amador Hospital
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215523061
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48.00 03/31/2025 Covered Recipient Teaching Hospital
Sutter Amador Hospital
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215523077
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48.00 02/28/2025 Covered Recipient Teaching Hospital
Sutter Amador Hospital
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215523067
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48.00 02/28/2025 Covered Recipient Teaching Hospital
Sutter Amador Hospital
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215523079
Principal investigator 1 Biogen, Inc. $3,000.00 02/21/2025 Covered Recipient Teaching Hospital
Cpmc-R.K. Davies Medical Center
A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer's Disease No dispute reported 06/30/2026 1236947314
Principal investigator 1 Alnylam Pharmaceuticals Inc. $25.00 02/17/2025 Covered Recipient Teaching Hospital
Sutter Amador Hospital
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215523063
Principal investigator 1 Alnylam Pharmaceuticals Inc. $95.01 02/17/2025 Covered Recipient Teaching Hospital
Sutter Amador Hospital
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215523065
Principal investigator 1 Eli Lilly and Company $105,655.00 02/11/2025 Covered Recipient Teaching Hospital
CPMC-R.K. DAVIES MEDICAL CENTER
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187873635
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48.00 01/31/2025 Covered Recipient Teaching Hospital
Sutter Medical Center - Sacramento
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy (cAPPricorn-1) No dispute reported 06/30/2026 1215523069
Principal investigator 1 Eli Lilly and Company $7,204.99 01/27/2025 Covered Recipient Teaching Hospital
CPMC-R.K. DAVIES MEDICAL CENTER
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187873637
Principal investigator 1 Eli Lilly and Company $561.98 01/09/2025 Covered Recipient Teaching Hospital
CPMC-R.K. DAVIES MEDICAL CENTER
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187873071